SCHEMBL10104511

SCHEMBL10104511

COc1c(C)cc(C(F)(F)F)cc1CN(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
SLC6A4 P31645 9/20 0.40
CYP2C19 P33261 2/20 0.39
HTT P42858 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HTR2A P28223 1/20 0.38
KCNH2 Q12809 1/20 0.38
SLC6A2 P23975 5/20 0.38
SLC6A3 Q01959 4/20 0.38
CYP1A2 P05177 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104434 0.85 CYP2C19 (0.56) CYP2D6SLC6A4CYP2C19HTTALOX15
SCHEMBL5110263 0.84 SLC6A4 (0.46) CYP3A4CYP2D6SLC6A4CYP2C19HTT
SCHEMBL10104519 0.82 HTT (0.35) SLC6A4HTTSLC6A2SMN1; SMN2KDM4E
SCHEMBL13130472 0.81 CYP2D6 (0.39) CYP3A4CYP2D6SLC6A4CYP2C19HTT
SCHEMBL14943430 0.79 TSHR (0.40) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL5110256 0.78 SLC6A4 (0.42) CYP3A4CYP2D6SLC6A4CYP2C19HTT
SCHEMBL15743685 0.78 RAPGEF4 (0.39) SMN1; SMN2ALDH1A1GAAL3MBTL1
SCHEMBL10104537 0.75 SLC6A4 (0.37) CYP3A4CYP2D6SLC6A4HTR2AKCNH2
SCHEMBL4941008 0.72 ACHE (0.43) CYP2D6SLC6A4HTR2AKCNH2SLC6A2
SCHEMBL10104475 0.72 CYP2C19 (0.41) CYP2D6CYP2C19HTTALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
WO-2009003998-A2 ANTIPROLIFERATIVE COMPOUNDS BASED ON 5-MEMBERED HETEROCYCLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 CYP3A4 1111/4885CYP2D6 554/4885SLC6A4 4238/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 CYP3A4 688/4885CYP2D6 470/4885SLC6A4 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.